XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenues:        
Total revenues $ 267,187 $ 135,673 $ 1,594,461 $ 2,965,579
Operating expenses:        
Research and development 22,376,575 22,486,266 41,487,763 46,876,155
General and administrative 11,071,510 5,850,101 18,519,864 12,825,129
Total operating expenses 33,448,085 28,336,367 60,007,627 59,701,284
Loss from operations (33,180,898) (28,200,694) (58,413,166) (56,735,705)
Other income (expense):        
Interest income 1,067,399 755,330 1,483,968 1,380,864
Interest expense (2,846,641) (2,194,783) (5,650,396) (2,851,031)
Change in fair value of derivative liability (97,755,000) 0 (110,976,977) 0
Gain (loss) on investment in affiliated entities (3,883,176) (173,212) 9,298,443 (923,315)
Net unrealized gain (loss) on available-for-sale equity securities 4,358,634 0 (691,458) 0
Other income (expense), net (152,102) 127,512 (577,602) 91,673
Gain on deconsolidation of Geneos 4,121,075 0 4,121,075 0
Net loss before income tax benefit and share in net loss of Geneos (128,270,709) (29,685,847) (161,406,113) (59,037,514)
Income tax benefit 0 106,771 0 169,571
Share in net loss of Geneos (901,757) 0 (901,757) 0
Net loss (129,172,466) (29,579,076) (162,307,870) (58,867,943)
Net loss attributable to non-controlling interest 469,407 191,850 1,063,757 261,455
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (128,703,059) $ (29,387,226) $ (161,244,113) $ (58,606,488)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders        
Basic and diluted (in dollars per share) $ (0.83) $ (0.30) $ (1.15) $ (0.60)
Weighted average number of common shares outstanding        
Basic and diluted (in shares) 155,807,054 98,083,896 140,215,158 97,795,910
Revenue under collaborative research and development arrangements        
Revenues:        
Total revenues $ 74,102 $ 64,283 $ 145,602 $ 2,834,995
Revenue under collaborative research and development arrangements with affiliated entities        
Revenues:        
Total revenues 95,146 71,390 1,267,272 126,970
Miscellaneous revenue        
Revenues:        
Total revenues $ 97,939 $ 0 $ 181,587 $ 3,614